BioXcel Therapeutics (NASDAQ:BTAI) Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of BioXcel Therapeutics (NASDAQ:BTAI) from a hold rating to a sell rating in a report published on Monday, Zacks.com reports.

According to Zacks, “BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. “

Other equities analysts have also issued research reports about the stock. HC Wainwright set a $25.00 price target on shares of BioXcel Therapeutics and gave the stock a buy rating in a report on Wednesday, June 5th. ValuEngine upgraded shares of BioXcel Therapeutics from a hold rating to a buy rating in a report on Thursday, August 8th.

Shares of NASDAQ:BTAI traded up $0.44 during mid-day trading on Monday, reaching $8.70. 1,015 shares of the company’s stock were exchanged, compared to its average volume of 27,267. The firm has a market cap of $136.85 million, a price-to-earnings ratio of -6.59 and a beta of 3.02. The firm’s fifty day simple moving average is $10.46. The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 0.04. BioXcel Therapeutics has a twelve month low of $2.41 and a twelve month high of $12.00.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.02). Sell-side analysts anticipate that BioXcel Therapeutics will post -2.22 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in BTAI. Northern Trust Corp lifted its holdings in BioXcel Therapeutics by 247.7% in the second quarter. Northern Trust Corp now owns 43,822 shares of the company’s stock valued at $481,000 after buying an additional 31,218 shares during the period. Creative Planning acquired a new position in BioXcel Therapeutics in the first quarter valued at $302,000. Renaissance Technologies LLC lifted its holdings in BioXcel Therapeutics by 59.8% in the second quarter. Renaissance Technologies LLC now owns 71,600 shares of the company’s stock valued at $785,000 after buying an additional 26,800 shares during the period. Bank of New York Mellon Corp acquired a new position in BioXcel Therapeutics in the second quarter valued at $198,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in BioXcel Therapeutics in the second quarter valued at $138,000. Institutional investors and hedge funds own 16.03% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Read More: What is a good dividend yield?

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.